New Tool for ER-Positive Breast Cancer May Predict Who Needs Chemotherapy

New Tool for ER-Positive Breast Cancer May Predict Who Needs Chemotherapy
casewesternlogo Researchers at Case Western Reserve University have found that the number of tubules in tumors may predict which women with estrogen receptor positive (ER+) breast cancer will benefit from hormone therapy alone and which require chemotherapy, providing a cheaper and faster alternative to genetic risk tests. The study, "Automated Tubule Nuclei Quantification and Correlation with Oncotype DX risk categories in ER+ Breast Cancer Whole Slide Images," published in the journal Scientific Reports, also describes a novel computer program that automatically counts tubules shown in whole slide images of breast cancer tissue specimens. The conundrum in the treatment and management of early-stage ER-positive breast cancer is identifying which cases are candidates for adjuvant chemotherapy and which patients will respond to hormonal therapy alone. Oncotype DX (ODX) and other gene expression tests allow clinicians to distinguish these patients, but such tests are usually expensive, harmful to tissue, and require shipping tissue samples for testing. Studies have shown that the grade of ER-positive breast cancer tumors highly correlates with the results of these genetic tests, suggesting that grading the tumors may be a possible approach to distinguish which patients should receive each type of therapy. However, w
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.